Skip to content

How Pharmaceutical Intervention Can Help Dialysis Patients Resolve Medication Issues: A Clinical Study

Pharmaceutical Intervention in Medication-Related Problems in Patients Undergoing Peritoneal Dialysis and Hemodialysis: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9835rf8
Enrollment
Unknown
Registered
2025-10-01
Start date
2025-01-13
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Chronic

Interventions

This is a participant-blinded, randomized clinical trial in which a total of 200 participants will be randomly allocated to one of the two study arms, with 100 in the intervention group and 100 in the
the allocation will be performed using Stratified Block Randomization to ensure that both dialysis types, Hemodialysis and Peritoneal Dialysis, are well-distributed between the groups, and allocation
Intervention Group: one hundred participants will receive standard care from the dialysis unit plus a pharmaceutical intervention consisting of two individualized counseling sessions with a pharmacist
Control Group: one hundred participants will receive only standard care, which consists of routine follow-up by the multidisciplinary team (doctors, nurses, nutritionists) of the dialysis unit, withou
F04.408.413

Sponsors

Universidade Estadual Paulista Julio de Mesquita Filho-Faculdade de Medicina-Câmpus de Botucatu.
Lead Sponsor
Universidade Estadual Paulista Julio de Mesquita Filho-Faculdade de Medicina-Câmpus de Botucatu.
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Individuals of both genders; aged 18 years or older; diagnosed with stage 5 Chronic Kidney Disease; undergoing Peritoneal Dialysis or Hemodialysis for at least 3 months; legally capable of signing the Informed Consent Form (ICF)

Exclusion criteria

Exclusion criteria: Cognitive impairment that prevents understanding the study or participating in the pharmaceutical consultations

Design outcomes

Primary

MeasureTime frame
It is expected that there will be proper use of medications by the research participants, and consequently, a reduction in polypharmacy

Secondary

MeasureTime frame
It is expected that there will be an increase in adherence to medication therapy and an improvement in the clinical condition, based on laboratory tests and patient reports

Countries

Brazil

Contacts

Public ContactLeandro Alvarado

Universidade Estadual Paulista Julio de Mesquita Filho-Faculdade de Medicina-Câmpus de Botucatu.

leandro.alvarado@unesp.br+55(14)99660-3060

Outcome results

None listed

Source: REBEC (via WHO ICTRP)